文献速递认知障碍与痴呆

淀粉样蛋白正电子发射断层扫描与轻度认知障碍或痴呆的医疗保险受益人的后续医疗服务使用

Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
PubMed 文献 · JAMA Neurol · 2023-01-01

IMPORTANCE: Results of amyloid positron emission tomography (PET) have been shown to change the management of patients with mild cognitive impairment (MCI) or dementia who meet Appropriate Use Criteria (AUC).…

要点

  • 淀粉样蛋白PET未显著降低12个月住院率(相对减少-4.49%,97.5%CI -9.09%至0.34%)。
  • 淀粉样蛋白PET未显著降低12个月急诊就诊率(相对减少-0.12%,97.5%CI -3.19%至3.05%)。
  • 淀粉样蛋白PET阳性者住院率21.4%低于阴性者25.7%(调整OR 0.83,95%CI 0.78-0.89)。

核心结论

  • 淀粉样蛋白PET与12个月住院或急诊就诊的显著减少无关。
  • 淀粉样蛋白PET阳性患者的住院率低于阴性患者。

研究设计与样本

  • 非随机对照试验,分析IDEAS研究(开放标签、多中心、纵向研究)的参与者,2016年2月至2017年12月入组,随访至2018年12月。
  • 参与者在全美595个提供专科记忆护理的临床中心招募,为65岁及以上、过去24个月内诊断轻度认知障碍或痴呆且符合已发表适当使用标准的医疗保险受益人。
  • 每位IDEAS研究参与者匹配一位未接受淀粉样蛋白PET的对照医疗保险受益人。
  • 两个队列各包含12684名成人,其中女性6467名(51.0%),中位(IQR)年龄77(73-81)岁。
  • 数据分析于2022年12月13日进行。

主要发现

  • 12个月内,IDEAS研究参与者住院比例为24.0%,匹配对照队列为25.1%,相对减少-4.49%(97.5%CI -9.09%至0.34%)。
  • 12个月急诊就诊率在两个队列几乎相同(IDEAS研究和对照队列均为44.8%),相对减少-0.12%(97.5%CI -3.19%至3.05%)。
  • 两个主要结局均未达到预设的10%或以上相对减少的效应量。
  • 淀粉样蛋白PET阳性参与者中1467/6848(21.4%)在12个月内住院,阴性参与者中1081/4209(25.7%)住院(调整OR 0.83,95%CI 0.78-0.89)。

关键数值与推荐

  • 主要终点为12个月住院和急诊就诊的患者比例。
  • 次要终点之一为淀粉样蛋白PET阳性与阴性参与者的住院率和急诊就诊率。
  • 预设效应量为相对减少10%或以上。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Results of amyloid positron emission tomography (PET) have been shown to change the management of patients with mild cognitive impairment (MCI) or dementia who meet Appropriate Use Criteria (AUC). OBJECTIVE: To determine if amyloid PET is associated with reduced hospitalizations and emergency department (ED) visits over 12 months in patients with MCI or dementia. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial analyzed participants in the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, an open-label, multisite, longitudinal study that enrolled participants between February 2016 and December 2017 and followed up through December 2018. These participants were recruited at 595 clinical sites that provide specialty memory care across the US. Eligible participants were Medicare beneficiaries 65 years or older with a diagnosis of MCI or dementia within the past 24 months who met published AUC for amyloid PET. Each IDEAS study participant was matched to a control Medicare beneficiary who had not undergone amyloid PET. Data analysis was conducted on December 13, 2022. EXPOSURE: Participants underwent amyloid PET at imaging centers. MAIN OUTCOMES AND MEASURES: The primary end points were the proportions of patients with 12-month inpatient hospital admissions and ED visits. One of 4 secondary end points was the rate of hospitalizations and rate of ED visits in participants with positive vs negative amyloid PET results. Health care use was ascertained from Medicare claims data. RESULTS: The 2 cohorts (IDEAS study participants and controls) each comprised 12 684 adults, including 6467 females (51.0%) with a median (IQR) age of 77 (73-81) years. Over 12 months, 24.0% of the IDEAS study participants were hospitalized, compared with 25.1% of the matched control cohort, for a relative reduction of -4.49% (97.5% CI, -9.09% to 0.34%). The 12-month ED visit rates were nearly identical between the 2 cohorts (44.8% in both IDEAS study and control cohorts) for a relative reduction of -0.12% (97.5% CI, -3.19% to 3.05%). Both outcomes fell short of the prespecified effect size of 10% or greater relative reduction. Overall, 1467 of 6848 participants (21.4%) with positive amyloid PET scans were hospitalized within 12 months compared with 1081 of 4209 participants (25.7%) with negative amyloid PET scans (adjusted odds ratio, 0.83; 95% CI, 0.78-0.89). CONCLUSIONS AND RELEVANCE: Results of this nonrandomized controlled trial showed that use of amyloid PET was not associated with a significant reduction in 12-month hospitalizations or ED visits. Rates of hospitalization were lower in patients with positive vs negative amyloid PET results.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Rabinovici GD, Carrillo MC, Apgar C, et al. Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA Neurol. 2023. PMID: 37812437. doi:10.1001/jamaneurol.2023.3490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。